Reviewing Pluri (PLUR) and Its Rivals

Pluri (NASDAQ:PLUR) is one of 846 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Pluri to related companies based on the strength of its risk, institutional ownership, analyst recommendations, dividends, earnings, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Pluri and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1	0	0	0	1.00
Pluri Competitors	9905	15274	45596	1595	2.54

As a group, “Biotechnology” companies have a potential upside of 99.35%. Given Pluri’s peers stronger consensus rating and higher probable upside, analysts clearly believe Pluri has less favorable growth aspects than its peers.

Profitability

This table compares Pluri and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pluri	-2,344.59%	N/A	-82.71%
Pluri Competitors	-12,285.98%	-196.04%	-30.61%

Insider & Institutional Ownership

16.6% of Pluri shares are held by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Pluri and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pluri	$1.02 million	-$23.82 million	-0.46
Pluri Competitors	$729.47 million	$11.46 million	-14.85

Pluri’s peers have higher revenue and earnings than Pluri. Pluri is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Pluri has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Pluri’s peers have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Summary

Pluri peers beat Pluri on 9 of the 13 factors compared.

About Pluri

Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.